Psoriasis. Psoriasis vulgaris
Conditions
Interventions
Intervention 1: Intervention group: patients were instructed to apply the niosome-curcumin ointment of 5 micromolar curcumin once a day for 4 weeks on their eligible skin lesions. Intervention 2: Comp
Sponsors
Gorgan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Parallel lesional skin of Psoriatic patient lesions from mild or severe form of disease Age >+18 Signing the informed consent form
Exclusion criteria
Exclusion criteria: Pregnant and lactation Suffering from autoimmune or other inflammation diseases Suffering from Cirrhosis and Hepatic disease Suffering from Metabolic syndrome Suffering from severe Renal disease Allergic reaction to Curcumin
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| IL23 gene expression. Timepoint: 4 weeks after local treatment with encapsulated curcumin by noisome. Method of measurement: Real time PCR and evaluating of gene expression exchange to control gene (18sRNA).;IL17 gene expression. Timepoint: 4 weeks after local treatment with encapsulated curcumin by noisome. Method of measurement: Real time PCR and evaluating of gene expression exchange to control gene (18sRNA).;TNFa gene expression. Timepoint: 4 weeks after local treatment with encapsulated curcumin by noisome. Method of measurement: Real time PCR and evaluating of gene expression exchange to control gene (18sRNA).;IL22 gene expression. Timepoint: 4 weeks after local treatment with encapsulated curcumin by noisome. Method of measurement: Real time PCR and evaluating of gene expression exchange to control gene (18sRNA).;S100A7 gene expresion. Timepoint: 4 weeks after local treatment with encapsulated curcumin by noisome. Method of measurement: Real time PCR and evaluating of gene expression exchange to control gene (18sRNA).;S100A12 gene expression. Timepoint: 4 weeks after local treatment with encapsulated curcumin by noisome. Method of measurement: Real time PCR and evaluating of gene expression exchange to control gene (18sRNA).;ßefensin2 gene expression. Timepoint: 4 weeks after local treatment with encapsulated curcumin by noisome. Method of measurement: Real time PCR and evaluating of gene expression exchange to control gene (18sRNA).;Ki67 gene expression. Timepoint: 4 weeks after local treatment with encapsulated curcumin by noisome. Method of measurement: Real time PCR and evaluating of gene expression exchange to control gene (18sRNA).;Accumulation of immune cells in lesional skin tissue. Timepoint: 4 weeks after local treatment with encapsulated curcumin by noisome. Method of measurement: H&E staining and optical microscopy.;Local disease severity. Timepoint: 4 weeks after local treatment with encapsulated curcumin by noisome. Method of measurement: Observ | — |
Secondary
| Measure | Time frame |
|---|---|
| Side effects (systemic and local). Timepoint: A phone number were given to patients for any emmergency call during treatment. Patient could report any side effects 24/7 as well as during follow-ups, all the way through the treatment and after completion. Method of measurement: Medical examination by the consultant dermatology. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactHanieh Kolahdooz
Golestan University of Medical Sciences
Outcome results
None listed